Skip to main content
Clinical Trials/NCT05698407
NCT05698407
Completed
Phase 4

Effect of Dexmedetomidine Plus Ropivacaine Versus Sufentanil Plus Ropivacaine for Epidural Labor Analgesia on Neonatal Outcomes: a Pilot Randomized Trial

Peking University First Hospital1 site in 1 country200 target enrollmentMarch 16, 2023

Overview

Phase
Phase 4
Intervention
Dexmedetomidine
Conditions
Pregnancy Related
Sponsor
Peking University First Hospital
Enrollment
200
Locations
1
Primary Endpoint
Composite neonatal morbidity
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Sufentanil-ropivacaine combination is commonly used for epidural labor anesthesia, but is associated with some adverse events. Dexmedetomidine is a high selective alpha2-adrenoceptor agonist. Mounting evidences show that dexmedetomidine-ropivacaine combination can also be used effectively for epidural labor analgesia. This pilot trial is designed to compare the effect of dexmedetomidine-ropivacaine combination versus sufentanil-ropivacaine combination on neonatal outcomes when used for epidural labor analgesia, and to test the feasibility of a future large randomized trial.

Detailed Description

Sufentanil combined with ropivacaine is commonly used for epidural labor anesthesia. However, this combination is associated with some adverse events including increased risk of neonatal depression. Dexmedetomidine is a high selective alpha2-adrenoceptor agonist and possesses opioid-sparing and analgesic effects when used in combination with local anesthetics. Recently published data suggest that dexmedetomidine-ropivacaine combination can effectively relieve labor pain. We suppose that, when compared with traditional sufentanil-ropivacaine combination, the dexmedetomidine-ropivacaine combination used for epidural labor analgesia may reduce sufentanil-related adverse neonatal outcomes. The purpose of this pilot trial is to compare the effect of dexmedetomidine-ropivacaine combination versus sufentanil-ropivacaine combination used for epidural labor analgesia on neonatal outcomes, and also to test the feasibility of a future large randomized trial.

Registry
clinicaltrials.gov
Start Date
March 16, 2023
End Date
August 28, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dong-Xin Wang

MD, PHD, Professor and Chairman

Peking University First Hospital

Eligibility Criteria

Inclusion Criteria

  • Aged 18-45 years;
  • Single term pregnancy with vertex presentation planning vaginal delivery;
  • Planning to receive epidural labor analgesia.

Exclusion Criteria

  • Presence of contraindications to epidural analgesia, which includes: (1) History of infectious disease of the central nervous system (poliomyelitis, cerebrospinal meningitis, encephalitis, etc.); (2) History of spinal or intra-spinal disease (trauma or surgery of spinal column, intra-spinal canal mass, etc.); (3) Systemic infection (sepsis); (4) Skin or soft tissue infection at the site of epidural puncture; (5) Coagulopathy.
  • Existence of bradycardia (heart rate \<60 bpm), hypotension (SBP \<90 mmHg) or severe hypertension (SBP ≥180mmHg), uncontrolled systemic comorbidities (i.e., diabetes or hepatic, renal or cardiac disease), American Society of Anesthesiologists (ASA) physical status ≥
  • History of psychiatric disease or epilepsia.
  • Allergy to study agents.
  • Other conditions that are considered unsuitable for study participation.

Arms & Interventions

Dexmedetomidine

loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine

Intervention: Dexmedetomidine

Sufentanil

loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine

Intervention: Sufentanil

Outcomes

Primary Outcomes

Composite neonatal morbidity

Time Frame: Up to 24 hours after birth

Included any of the following: 1-min or 5-min Apgar score less than 7, umbilical cord arterial PH less than 7.1, requirement for immediate assisted ventilation, neonatal intensive care unit or neonatal ward admission within 24 hours after birth.

Secondary Outcomes

  • Delivery mode(At the time of delivery)
  • Epidural infusion volume(From the begining of epidural analgesia until childbirth, up to 20 hours)
  • Duration of labor(From the begining of the first stage of labor until delivery of the placenta, up to 20 hours)
  • The depression score assessed by Edinburgh Postnatal Depression Scale (EPDS)(At 42 days after childbirth)
  • Subjective sleep quality score at the first night after childbirth(Up to 24 hours after childbirth)

Study Sites (1)

Loading locations...

Similar Trials